Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
$11.17
-2.2%
$12.25
$10.06
$15.15
$1.46B1.262.03 million shs1.92 million shs
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$9.12
$9.20
$4.30
$13.66
$458.93M1.531.18 million shsN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$2.29
-23.2%
$2.96
$1.79
$4.70
$301.54M1.57819,049 shs2.55 million shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$3.70
-4.1%
$5.14
$2.36
$7.22
$111.63M0.19249,252 shs85,873 shs
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
$1.08
$0.77
$5.95
$187.12M1.712.01 million shs2.13 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
-2.89%-0.09%-8.64%-16.95%+6.43%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.00%0.00%0.00%0.00%0.00%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
0.00%+6.81%+13.74%-18.36%+52.04%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-1.28%-17.52%-21.22%+6.63%+53.78%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
4.4099 of 5 stars
3.41.00.04.72.82.51.9
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.2938 of 5 stars
0.00.00.04.30.01.70.6
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
3.5187 of 5 stars
3.30.00.04.30.62.51.3
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
3.2197 of 5 stars
2.01.00.04.42.53.30.6
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
2.75
Moderate Buy$25.00123.81% Upside
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
2.67
Moderate Buy$4.83111.52% Upside
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/A$25.00575.68% Upside
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A

Current Analyst Ratings

Latest ORGO, ZIOP, DVAX, RLMD, and FLXN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/1/2024
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$5.00
2/23/2024
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/7/2024
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$5.00
2/1/2024
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$20.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
$232.28M6.29N/AN/A$4.81 per share2.32
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$85.55M5.36N/AN/A($0.34) per share-26.82
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$433.14M0.70$0.16 per share13.86$2.11 per share1.08
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/A$2.84 per shareN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A$0.58 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
-$6.39M-$0.06N/A25.98N/A-2.75%-1.08%-0.66%5/8/2024 (Confirmed)
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$4.95M$0.0457.14N/A1.14%1.81%1.09%5/9/2024 (Confirmed)
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$98.79M-$3.28N/AN/AN/AN/A-93.44%-85.11%5/9/2024 (Estimated)
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/A

Latest ORGO, ZIOP, DVAX, RLMD, and FLXN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
-$0.03N/A+$0.03N/AN/AN/A  
5/8/2024N/A
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
-$0.04N/A+$0.04N/AN/AN/A
3/19/2024Q4 2023
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.88-$0.84+$0.04-$0.84N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
N/AN/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
0.41
13.81
12.96
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/A
4.38
4.05
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
0.22
2.80
2.44
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/A
8.00
8.00
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.18
3.43
3.43

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
96.96%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
90.01%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
49.57%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
45.24%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
51.03%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
408130.86 million126.96 millionOptionable
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
25750.32 million45.73 millionOptionable
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
862131.96 million87.10 millionOptionable
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
2030.17 million26.10 millionOptionable
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
105216.15 million204.91 millionOptionable

ORGO, ZIOP, DVAX, RLMD, and FLXN Headlines

SourceHeadline
Childhood CancersChildhood Cancers
curetoday.com - February 17 at 5:57 PM
Alx Oncology Holdings (ALXO)Alx Oncology Holdings (ALXO)
investing.com - February 10 at 8:15 PM
Pediatric Hematology-Oncology FellowshipPediatric Hematology-Oncology Fellowship
bcm.edu - February 5 at 8:39 AM
Alaunos Therapeutics: Other Events, Financial Statements And ExhibitsAlaunos Therapeutics: Other Events, Financial Statements And Exhibits
cbonds.com - January 31 at 9:44 AM
CG Oncology IncCG Oncology Inc
reuters.com - January 31 at 4:43 AM
Oncology Nurses Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer PatientsOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients
medscape.com - December 21 at 3:43 PM
Immuno-OncologyImmuno-Oncology
ajmc.com - December 19 at 3:21 PM
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
markets.businessinsider.com - December 18 at 8:18 AM
Exploring Patient-Centered Handoffs in Surgical OncologyExploring Patient-Centered Handoffs in Surgical Oncology
medscape.com - December 10 at 7:36 PM
Association of Community Cancer CentersAssociation of Community Cancer Centers
ajmc.com - October 14 at 2:50 PM
Oncology News and ResearchOncology News and Research
news-medical.net - September 19 at 5:53 PM
WBSPH 2024 - OncologyWBSPH 2024 - Oncology
newsweek.com - September 15 at 8:49 PM
Kris on OncologyKris on Oncology
medscape.com - September 6 at 11:16 PM
Gauging Ziopharms Chances for Positive Sarcoma Drug Trial ResultsGauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results
thestreet.com - August 29 at 6:23 AM
Oncology Cases & QuizzesOncology Cases & Quizzes
medscape.com - August 14 at 6:15 PM
Ziopharm’s palifosfamide fails in first-line STS…Ziopharm’s palifosfamide fails in first-line STS…
investing.com - June 21 at 12:05 AM
Weber on OncologyWeber on Oncology
medscape.com - June 19 at 2:11 PM
A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in MelanomaA Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma
ascopubs.org - June 17 at 8:43 AM
ALX Oncology Holdings Inc Ordinary SharesALX Oncology Holdings Inc Ordinary Shares
morningstar.com - June 15 at 6:54 PM
Division of Pediatric Hematology and OncologyDivision of Pediatric Hematology and Oncology
slu.edu - June 13 at 3:50 PM
Division of Hematology and Medical OncologyDivision of Hematology and Medical Oncology
slu.edu - June 13 at 3:50 PM
Intratumoral Cancer Therapies Global Market Report 2023Intratumoral Cancer Therapies Global Market Report 2023
finance.yahoo.com - June 9 at 1:32 PM
Natural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.coNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.co
marketwatch.com - May 11 at 9:52 PM
VC Identifies 3 Startups That Will Shake Up the Future of Cancer CareVC Identifies 3 Startups That Will Shake Up the Future of Cancer Care
medcitynews.com - May 10 at 1:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Dynavax Technologies logo

Dynavax Technologies

NASDAQ:DVAX
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
Flexion Therapeutics logo

Flexion Therapeutics

NASDAQ:FLXN
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.
Organogenesis logo

Organogenesis

NASDAQ:ORGO
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Relmada Therapeutics logo

Relmada Therapeutics

NASDAQ:RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
ZIOPHARM Oncology logo

ZIOPHARM Oncology

NASDAQ:ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.